04 April 2024
04 April 2024
Zevtera can treat staphylococcus aureus bloodstream infections, acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Bavarian Nordic’s Jynneos, the only FDA-approved vaccine for mpox, recently made headway into the US commercial market.
The approval is based on the findings from the multicentre, randomised, placebo-controlled Phase II PAGE study.
Appili is advancing ATI-1701, a live attenuated vaccine for Francisella tularensis.
The merged business will focus on late-stage cancer treatments, expecting to begin Phase III trials for a new therapy.
The Massachusetts-based Obsidian’s cancer cell therapy OBX-115 will need to catch up with competitor Iovance’s Amtagvi.
The company will focus on advancing its agonist antibody therapeutics developed using the Diagonal platform.
Using real-world data, proactive signal detection may have a transformative effect on pharma’s ability to efficiently report adverse events.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
